You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-7 of 7 results found

Processes for Producing and Purifying Nucleic Acid-Containing Compositions

This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
  • Therapeutics

Topical Sodium Nitrate Ointment for Sickle Cell Disease

The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
  • Therapeutics

Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs

Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
  • Therapeutics

T-Cell Therapy Against Patient-Specific Cancer Mutations

Scientists at the National Cancer Institute developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations
  • Therapeutics

T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy

Researchers at the National Institutes of Health have identified a collection of TCRs that exclusively recognize the common hotspot driver mutations in KRAS antigen, expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of specific Class I/Class II HLA alleles. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.
  • Therapeutics

T-Cell Therapy Against Patient-Specific Cancer Mutations

Scientists at the National Cancer Institute's Surgery Branch developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. The NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations.
  • Therapeutics